Last reviewed · How we verify
CRCHUM-MT cocktail
CRCHUM-MT is a multi-target immunotherapy cocktail designed to enhance anti-tumor immune responses through combined modulation of immune checkpoints and tumor microenvironment.
CRCHUM-MT is a multi-target immunotherapy cocktail designed to enhance anti-tumor immune responses through combined modulation of immune checkpoints and tumor microenvironment. Used for Advanced or metastatic cancer (specific indications not publicly detailed).
At a glance
| Generic name | CRCHUM-MT cocktail |
|---|---|
| Also known as | omeprazole, Losec, caffeine, Wake-up, bupropion |
| Sponsor | Centre hospitalier de l'Université de Montréal (CHUM) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
The CRCHUM-MT cocktail is an experimental combination therapy developed at Centre hospitalier de l'Université de Montréal that targets multiple pathways in cancer immunotherapy. While specific components are not fully disclosed in public literature, such cocktails typically combine checkpoint inhibitors, cytokine modulators, or other immunomodulatory agents to overcome resistance mechanisms and improve therapeutic efficacy in difficult-to-treat cancers.
Approved indications
- Advanced or metastatic cancer (specific indications not publicly detailed)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CRCHUM-MT cocktail CI brief — competitive landscape report
- CRCHUM-MT cocktail updates RSS · CI watch RSS
- Centre hospitalier de l'Université de Montréal (CHUM) portfolio CI